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because the prognostic factors for this disease are not well established it has proved difficult to identify those patients who will ultimately respond to current treatment protocols. This reduces the efficient use of existing treatment regimens and the development of new therapies for non-responders.
Various clinical disease features such as patient age (Jenkin et al.. 1990; Zerbini et al., 1993) , sex (Bloom et al., 1969; Berry et al., 1981; Zerbini et al., 1993) and degree of surgical resection (Jenkin et al., 1990; Zerbini et al., 1993) have proved unreliable in predicting disease outcome. Only the presence of metastases at diagnosis (Allen and Epstein, 1982; Kopelson et al., 1983; Caputy et al., 1987; Jenkin et al., 1990; Zerbini et al., 1993) and use of posterior fossa radiotherapy dosage <50Gy (Berry et al., 1981; Kopelson et al., 1983; Zerbini et al.. 1993) In recent years biological disease markers have improved the accuracy of prognostic prediction for many tumours. Moreover, the development of immunohistochemical techniques has permitted their rapid and widespread investigation. One such group of markers are oncogenes and their protein products. In the present study we investigated the expression and prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma. This oncogene has previously been extensively studied in breast cancer, demonstrating a significant relationship between overexpression of its product by tumour cells and poor prognosis (Slamon et al., 1989; Gullick et al., 1991; Lovekin et al., 1991; Winstanley et al., 1991) . The rodent counterpart of the c-erbB-2 gene, termed c-neu, was first identified in transplacentally induced rat neuroectodermal tumours of the central nervous system, providing evidence for the involvement of this oncogene in the development of central neuroectodermal tumours (Schecter et al., 1984) . In addition, the commonest chromosomal abnormality in medulloblastoma is an iso-chromosome of the long arm of chromosome 17 (iso 17q) (Bigner et al., 1988) . The c-erbB-2 gene is located on the long arm of chromosome 17 (Fukushige et al., 1986) and so is potentially involved in the abnormality.
.Materias and methods
Sixty-five children less than 15 years of age with medulloblastoma were notified to the Northern Region Young People's Malignant Disease Registry between 1968 and 1988 (Craft et al.. 1987 . Four of these patients died in the post-operative period from surgical complications. Tumour material was not available for six patients. The tumours from the remaining 55 patients were studied. The age at diagnosis ranged from I month to 14 years with a mean of 6.3 years. Thirty-seven patients were male and 18 female. Fifty-three of the patients received a combination of surgery (total, partial or biopsy resection) with post-operative posterior fossa and craniospinal radiotherapy. Two patients were subjected to surgery alone. In addition, 24 patients received post-operative chemotherapy. In all but two this included vincristine with or without CCNU. The remaining patients received cyclophosphamide and 5-fluorouracil or 8 in 1 therapy (vincristine, cyclophosphamide, methylprednisolone, CCNU, procarbazine, cisplatin, hydroxyurea and cytosine) .
The vast majority of patients had no accurate information regarding disease stage at diagnosis. This lack of data reflected both a deficiency in sensitive and routinely available imaging techniques over the period 1968-88 and the absence of a uniformly accepted method of disease staging. Therefore disease stage could not be analysed as a prognostic factor in this study.
All experimental procedures were performed using 10% formalin-fixed paraffin embedded tumour material obtained from the patients at operation. For each case, all available tumour blocks were collected for study from the Newcastle and Middlesbrough Neuropathology archives and diagnosis was confirmed by RHP.
The monoclonal antibody NCL-CB1 1, generated to a synthetic peptide sequence of predicted antigenicity near the C-terminus of the protein (Corbett et al., 1990) , was used to detect the c-erbB-2 oncogene product in tumour sections by the avidin-biotin-peroxidase complex technique (Hsu et al., 1981 in TBS, binding of the primary antibody was demonstrated with a standard avidin-biotin-peroxidase complex technique (Vectastain). This method employs a biotinylated sheep antimouse antibody solution followed by a colorant reaction of 0.5% diaminobenzidine and hydrogen peroxide in TBS. Sections were then counteredstained with haematoxylin. Four controls were employed. As negative controls either primary or secondary antibodies were substituted for normal serum in the staining protocol. In addition, an antigen absorption control was performed using primary antibody first incubated with its antigen. Finally breast carcinoma tissue known to express the c-erbB-2 protein was employed as a positive control.
All analyses were performed blind on separate occasions by RHP and RJG. Discrepancies in staining analysis occurred in seven cases. These were re-examined on a multiheaded microscope and consensus reached. Staining was scored for three parameters: pattern of section staining, intensity of tumour cell stain and estimated percentage of section staining. Patient survival was assessed using Kaplan-Meier survival curves and the log-rank test (Peto and Pike, 1973) . Initial analysis was performed to compare the prognosis of those patients receiving chemotherapy, surgery and radiotherpy with those undergoing surgery and radiotherapy alone. No significant survival difference was observed between these two groups (P = 0.80). Similar analysis of patient age, sex, posterior fossa radiotherapy dose greater or less than 50 Gy and degree of surgical resection (total vs partial resection) for the study population also failed to reveal any prognostic signifi of these variables (P = 0.99, 0.99, 0.23 and 0.50 respectively). The population was therefore analysed as a single group in all subsequent analysis of c-erbB-2 expression and survival.
Following univariate analysis the continuous variable 'percentage of positive tumour cells' was analysed in the Cox regression model with other variables including age, sex, posterior radiotherapy dose and degree of surgical resection received (Cox, 1972) . This allowed the further assessment of its independent prognostic significance without the risk of 'data-driven' categorisation.
Resdts
Forty-six of the 55 tumours (83.6%) expressed the c-rbB-2 product (Figure 1) tumour cell c-erbB-2 product expression. Scale bar =20 pm.
of medulloblastoma cells rendered difficult the distinction between cytoplamic and membrane-associated c-erbB-2 immunoreactivity. The rmaining nine (16.4%) showed no evidence of reactivity. All control sections were negative (Figure 2 On a semiquantitative 1-4 scale, positive sections were scored as either 0, +, + + or + + + based on the most frequent intensity pattern observed within tumour sections. Twenty-two (47.8%) positive tumours had a predominance of intensely staining cells (+ + +), while moderate positivity (+ +) was seen in 18 (39.1%) and faint positivity (+) in the remaining six (13.1%).
The estimated percentage of tumour calls demonstrating c-erbB-2 product immunoreactiity within sections ranged from less than 10% to more than 80%. Twenty-thre cases (50%) had an estimated section positivity of more than 50% In contrast, the percentage of tumour cells expressing the c-erbB-2 product proved to be a significnt indicator of patient outcome when analysed as both a categorical and continuous vanable. As a categorical variable patients were divied into two groups: more or less than 50% tumour cells. The survival curve for these two categories is shown in Figure 8 . Patients with more than 50% positive tumour cells had a signntly worse survival, with only 10% alive at 10 years vs 48% for those with less than 50% positive tumour cells (log rank P = 0.0049). To demonstrate that this observed prognostic signifi was independent and not a result of 'data driven' categorisation, it was also entered into the Cox model as a continuous variable with other variables. These included age, sex, degree of surgical resection and posterior fossa radiotherapy dose. Only c-erbB-2 oncogene product expression retained prognostic signif with P= 0.038.
Disde
This study has demonstrated tumour cell expression of the c-erbB-2 oncogene product in a high proportion (83.6%) of childhood medulloblastomas. In addition, it reveals a significant relationship between the number of tumour cells expressing this oncogene product and patient prognosis.
Patients whose tumours had c-erbB-2 immunoreactivity in less than 50% of tumour cells had a significantly improved 10 year survival in both log-rank and Cox analyses when compared with patients in whom more than 50% of tumour cells were positive for c-erbB-2 product. No significant relationship between patient survival and either the intensity of tumour cell staining or the distribution of positive cells was found. This lack of prognostic signifi may relate to the small size of our study population, and further analysis is required before these two variables can be dismised as being of no prognostic value.
The sparse rim of cytoplasm characteristic of primitive neuroectodermal tumour (PNET) cells rendered it difficult to attribute cell product immunostaining to membrane or cytop- lasm. The c-erbB-2 oncogene encodes a transmembrane growth factor receptor. However, both membrane and cytoplasmic expression is a well-recognised feature of c-erbB-2 (Gullick et al., 1987; Corbett et al., 1990; Winstanley et al., 1991) and other members of the receptor tyrosine kinase family, including the epidermal growth factor receptor (EGFR) and the more recently described c-erbB-3 receptor (Poller et al., 1992) . Although cytoplasic immunoreactivity has been proposed to represEnt post-translational processing of receptor protein before membrane insertion, this remains controversial (Poller et at., 1992) .
In addition to tumour cell expresson, specific nnmunostaining of several normal tissues was also demonstrated. This included heterogeneous staining of neurones and Purkinje cells, vascular endothelium and smooth muscle. Expression of c-erbB-2 by these normal tisues has been described in both human (Quirke et al., 1989) and rat (Kokai et al., 1987) fetuses. However, expression by mature human nervous tissue has not been consistently demonstrated (Natali et al., 1990 Press et al., 1990 . In recent years various mechanisms have been proposed for the employment of antibodies directed against the c-erbB-2 product in the treatment of tumours expressing this protein. These include the enh nmt of T-cell cytotoxicity (Shalaby et al., 1992) , use as immunotoxins and cytotoxin targeting or immunotherapy (Tagliabue et al., 1991) . Cearly, before such techniques could be considered an in-depth understanding of the expression of cerbB-2 protein by normal tissues such as those described in the present study would be required. Finally, various hypotheses have been suggested to explain the potential mechanism by which c-erbB-2 may initiate and promote malignant transformation. As stated earler, the cerbB-2 oncogene encodes a tranembrane growth factor receptor. Abnormalities in either the quality or quantity of c-erbB-2 product expressed with or without interaction with its native ligand may therefore lead to breakdown in the control of normal mitogenic signal transduction (Bargmann and Wienberg, 1988; Di Fiore et al., 1990) . With regard to ligand interactions, Marchionni et al. (1993) have recently described a family of potential ligands for the c-erbB-2 receptor collectively termed the neureguln. When exposed to c-erbB-2-expressing cells, these proteins cause phosphorylation of the c-erbB-2 receptor and cell proliferation. Demonstration of neuregulin expression in the developing nervous system has led to the proposal that paracrine and autocrine procses involving c-erbB-2 recptor and ligand may play a key role in the development of early central nervous system tumours (Marchionni et al., 1993) . At the receptor level studies in human tumours have demonstrated overexpression of an otherwise normal c-erbB-2 product, leading to uncontrolled mitogenic signalling. One process by which overexpression may be achieved is-oncogene amplification. This is principally a feature of adenocarcinomas (Yokota et al., 1986) and has been described in breast (Yokota et al., 1986; Bg et al., 1988; Slamon et al., 1989 ), gastric (Fukushige et al., 1986 Kameda et al., 1990 ), renal (Yokoto et al., 1986 and colonic tumours (Guttman et al., 1989) . To date there have been no studies of the c-erbB-2 gene locus in medulloblastoma, and so it is unclar by what mechanism the oncogene is activated. However, the normal proto-oncogene c-erbB-2 maps to the long arm of chromsome 17 at q21 (Fukushige et al., 1986) . The principal non-random chromosomal abnormality of medulloblastoma is an iso-chromosome of the long arm chromosome 17, which can be present in multiple copies (Bigner et al., 1988) . This potentially results in the presence of multiple copies of the c-erbB-2 oncogene and hence a mechanisn by which the gene may be 'amplified'. In the present study expression of the c-erbB-2 product was observed in 83.6% of cases, however the iso 17q abnormality is present in only 30-40% of medulloblastomas . (Bigner et al., 1988; Griffin et al., 1988; Biegel et al., 1989; Stewart et al., 1990) . This chromosomal abnormality is therefore unlikely to be the only potential cause of c-erbB-2 overexpression in this malignancy.
This study has demonstrated the expression of c-erbB-2 oncogene product in a high proportion of childhood mauloblastomas. In addition, the percentage of tumour cells expressing the c-erbB-2 product is signifiantly and independently related to patient prognosis. Further analysis of c-erbB-2 oncogene in medulloblastoma and normal nervous tissw is required to undentand fully its potential role in both the pathogenesis of this malignancy and future immunotherapy. 
